Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity
Svetlana O. Doronina(Seagen (United States)), Peter D. Senter(Seagen (United States)), Charles G. Cerveny(Seagen (United States)), Roger F. Zabinski(Seagen (United States)), Brian A. Mendelsohn(Seagen (United States)), Ezogelin Oflazoglu(Seagen (United States)), Tim D. Bovee(Seagen (United States)), Stephen C. Alley(Seagen (United States)), Alan F. Wahl(Seagen (United States)), Brian E. Toki(Seagen (United States)), Russell J. Sanderson(Seagen (United States)), Damon L. Meyer(Seagen (United States))
Cited by 511
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
|Blood|2003|918
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772